A little more than a year after taking on the role, the CEO of Editas Medicines is preparing to pass the torch, continuing a series of executive changes at the gene editing company.
Effective June 1, Jim Mullen will be replaced by Gilmore O’Neill, who most recently served as the chief medical officer at another company heavily invested in gene therapy research, Sarepta Therapeutics. Mullen isn’t cutting ties with Editas, though. He will stay on as executive chairman of the company’s board of directors, a position he held before and during his time as CEO.
“Unlike some of the things that we’ve seen in the past, this is a very mindful, thoughtful transition,” said Mullen, in an interview.
Editas hit a major milestone while under Mullen’s leadership, producing data from the first clinical trial of a treatment made with CRISPR gene editing technology that works inside the body. Yet Editas, like many of its peers, has also seen its stock price fall significantly over the past year. Though investors have pulled back from the biotechnology sector on a broad scale, the impact has appeared particularly large among genetic medicine developers.
Despite its status as one of the most advanced CRISPR-focused biotechs, departures and arrivals have been fairly commonplace in Editas’ top ranks over the past several years. Executives overseeing scientific research, finance and clinical development programs have left. And two months ago, the shake-ups continued with the firing of the company’s chief medical officer, Lisa Michaels.
Editas has also had three different CEOs since 2014. Mullen, who took the reins from Cynthia Collins last February, had previously held the same position at Biogen as well as Patheon, the contracted drug manufacturer bought by Thermo Fisher. READ MORE
by Jacob Bell
Source: biopharmadive.com
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
